HomeCompareKYCCF vs ABBV

KYCCF vs ABBV: Dividend Comparison 2026

KYCCF yields 0.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KYCCF wins by $4.05M in total portfolio value· pulled ahead in Year 6
10 years
KYCCF
KYCCF
● Live price
0.97%
Share price
$359.20
Annual div
$3.49
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.15M
Annual income
$3,465,086.00
Full KYCCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KYCCF vs ABBV

📍 KYCCF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKYCCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KYCCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KYCCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KYCCF
Annual income on $10K today (after 15% tax)
$82.59/yr
After 10yr DRIP, annual income (after tax)
$2,945,323.10/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KYCCF beats the other by $2,924,267.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KYCCF + ABBV for your $10,000?

KYCCF: 50%ABBV: 50%
100% ABBV50/50100% KYCCF
Portfolio after 10yr
$2.13M
Annual income
$1,744,928.88/yr
Blended yield
82.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KYCCF
No analyst data
Altman Z
57.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KYCCF buys
0
ABBV buys
0
No recent congressional trades found for KYCCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKYCCFABBV
Forward yield0.97%3.06%
Annual dividend / share$3.49$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$4.15M$102.3K
Annual income after 10y$3,465,086.00$24,771.77
Total dividends collected$4.07M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KYCCF vs ABBV ($10,000, DRIP)

YearKYCCF PortfolioKYCCF Income/yrABBV PortfolioABBV Income/yrGap
1$10,894$194.32$11,550$430.00$656.00ABBV
2$12,053$395.70$13,472$627.96$1.4KABBV
3$13,715$818.26$15,906$926.08$2.2KABBV
4$16,415$1,740.36$19,071$1,382.55$2.7KABBV
5$21,458$3,893.53$23,302$2,095.81$1.8KABBV
6← crossover$32,473$9,513.27$29,150$3,237.93+$3.3KKYCCF
7$61,656$26,910.18$37,536$5,121.41+$24.1KKYCCF
8$161,475$95,503.37$50,079$8,338.38+$111.4KKYCCF
9$640,293$467,514.63$69,753$14,065.80+$570.5KKYCCF
10$4,150,200$3,465,086.00$102,337$24,771.77+$4.05MKYCCF

KYCCF vs ABBV: Complete Analysis 2026

KYCCFStock

Keyence Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of factory automation solutions in Japan, China, the United States, and internationally. The company offers photoelectric, fiber optic, laser, positioning, vision, and inductive proximity sensors, as well as network communication units. It also provides measurement sensors, such as laser displacement and profiler, optical/laser micrometer, inductive displacement sensor, 3D interference measurement, spectral interference displacement, and contact displacement/LVDT sensors; and measurement systems, including optical comparators, 3D scanners, and CMM/laser trackers. In addition, the company provides safety products comprising safety laser scanners, light curtains, interlock switches, and controllers; and pressure, flow, level, and temperature sensors for monitoring equipment processes. Further, it offers static eliminators/ionizers and electrostatic sensors, which protect workers, machinery, and products from the damaging effects of electrostatic charge; vision systems and sensors; and programmable logic controllers and other controls that are used for machine control applications. Additionally, the company provides barcode and handheld scanners; laser marking systems/laser markers and industrial continuous inkjet printers; digital, 3D surface profilers, elemental analyzers, optical profilometers, and fluorescence microscopes; data loggers; and handheld mobile computers. It serves customers in automotive/chassis assembly, metals/machining, FPD/glass, semiconductor/ICS, plastic/molding, food/pharmaceutical, steel, and other industries. Keyence Corporation was founded in 1972 and is headquartered in Osaka, Japan.

Full KYCCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KYCCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KYCCF vs SCHDKYCCF vs JEPIKYCCF vs OKYCCF vs KOKYCCF vs MAINKYCCF vs JNJKYCCF vs MRKKYCCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.